Pharma company executives debate drug pricing increases

The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies. AbbVie Inc on Wednesday became the third global drugmaker to publicly promise to cap annual price increases at under 10 percent, following earlier pledges by Allergan Plc and Novo Nordisk A/S . "I do think that the industry is off to a good start in terms of good behavior," Allergan Chief Executive Officer Bre